• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

ASH: Gilead touts 'astounding' Yescarta survival results at 3 years

cafead

Administrator
Staff member
  • cafead   Dec 08, 2019 at 10:42: PM
via How long can a single infusion of Gilead Sciences CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, the company showed Saturday.

article source
 

<